• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Henry Schein Inc.

    12/13/24 8:43:40 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    S-8 1 d896440ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on December 13, 2024

    Registration No. 333-________

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    HENRY SCHEIN, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware
       11-3136595

    (State or other jurisdiction of

    incorporation or organization)

      

    (I.R.S. Employer

    Identification No.)

    135 Duryea Road

    Melville, New York

       11747
    (Address of Principal Executive Offices)    (Zip code)

    Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan

    (f/k/a Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan, as amended)

    and

    Henry Schein, Inc. 2024 Stock Incentive Plan

    (f/k/a Henry Schein, Inc. 2020 Stock Incentive Plan, as amended)

    (Full title of the plan)

    Kelly Murphy, Esq.

    Senior Vice President and General Counsel

    Henry Schein, Inc.

    135 Duryea Road

    Melville, New York 11747

    (Name and address of agent for service)

    631-843-5500

    (telephone number, including area code, of agent for service)

     

     

    Copies of all communications to:

    Michael E. Ellis, Esq.

    Proskauer Rose LLP

    Eleven Times Square

    New York, New York 10036

    212-969-3000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This registration statement relates to the registration of (i) 275,000 additional shares of common stock, par value $.01 per share (“Common Stock”), of Henry Schein, Inc. (the “Company” or the “registrant”) reserved for issuance under the Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan, as amended from time to time, f/k/a the Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan (the “2023 Non-Employee Director Plan”), and (ii) 4,800,000 additional shares of Common Stock reserved for issuance under the Henry Schein, Inc. 2024 Stock Incentive Plan, as amended from time to time, f/k/a the Henry Schein, Inc. 2020 Stock Incentive Plan (the “2024 Plan”). Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers any additional shares of Common Stock that become issuable under the 2023 Non-Employee Director Plan and the 2024 Plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged.

    Pursuant to General Instruction E to Form S-8, the following registration statements on Form S-8 previously filed by the Company with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this registration statement, except as the same may be modified by the information set forth herein:

     

    File No.

      

    Date

    333-31544

      

    April 19, 2000

    333-91778

      

    July 2, 2002

    333-111914

      

    January 14, 2004

    333-164360

      

    January 15, 2010

    333-192788

      

    December 12, 2013

    333-212994

      

    August 8, 2016

    333-253633

      

    February 26, 2021

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit

    Number

      

    Description

      4.1    Second Amended and Restated Certificate of Incorporation of Henry Schein, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on June 1, 2018)
      4.2    Fourth Amended and Restated By-Laws of Henry Schein, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on March 24, 2023)
      5.1    Opinion of Proskauer Rose LLP*
     23.1    Consent of BDO USA, P.C.*
     23.2    Consent of Proskauer Rose LLP (included in Exhibit 5.1)*
     24.1    Powers of Attorney (included on signature page)

     

    2


     10.1    Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan, as amended and restated effective as of May 23, 2023 (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 25, 2023)
     10.2    Henry Schein, Inc. 2024 Stock Incentive Plan, as amended and restated effective as of May  21, 2024 (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 24, 2024)
    107    Filing Fee Table*

     

    *

    filed herewith

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Melville, State of New York, on December 13, 2024.

     

    HENRY SCHEIN, INC.
    By:  

    /s/ Stanley M. Bergman

      Name:   Stanley M. Bergman
      Title:   Chairman and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Stanley M. Bergman and Ronald N. South, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, to act, without the other, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Henry Schein, Inc., and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed on December 13, 2024, by the following persons in the capacities indicated:

     

    Signatures

      

    Title

    /s/ Stanley M. Bergman

    Stanley M. Bergman

      

    Chairman and Chief Executive Officer (Principal Executive Officer)

    /s/ Ronald N. South

    Ronald N. South

       Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)


    /s/ Mark E. Mlotek

    Mark E. Mlotek

      

    Director, Executive Vice President and Chief Strategic Officer

    /s/ Mohamad Ali

    Mohamad Ali

      

    Director

    /s/ Deborah Derby

    Deborah Derby

      

    Director

    /s/ Carole T. Faig

    Carole T. Faig

      

    Director

    /s/ Joseph L. Herring

    Joseph L. Herring

      

    Director

    /s/ Kurt P. Kuehn

    Kurt P. Kuehn

      

    Director

    /s/ Philip A. Laskawy

    Philip A. Laskawy

      

    Director

    /s/ Anne H. Margulies

    Anne H. Margulies

      

    Director

    /s/ Carol Raphael

      

    Director

    Carol Raphael   

    /s/ Scott Serota

      

    Director

    Scott Serota   

    /s/ Bradley T. Sheares, Ph.D.

    Bradley T. Sheares, Ph.D.

      

    Director

    /s/ Reed V. Tuckson, M.D., FACP

      

    Director

    Reed V. Tuckson, M.D., FACP   
    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Global Dist. & Tech. Albertini Andrea covered exercise/tax liability with 2,032 shares, decreasing direct ownership by 3% to 65,900 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/11/25 4:14:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/9/25 9:05:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 140 units of Common Stock par value $0.01 per shre and gifted 500 shares, decreasing direct ownership by 0.20% to 319,877 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    11/26/25 4:10:29 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 4:05:30 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 7:00:20 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Third Quarter 2025 Conference Call on Tuesday, November 4, 2025, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2025 financial results before the stock market opens on Tuesday, November 4, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Sc

    10/21/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care